Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck

Annals of Oncology

Volumn 22, Issue 11, 2011, Pages 2501-2507

  Villaflor, V M ^a   Haraf, D ^b   Salama, J K ^b,c   Kocherginsky, M ^b   Langerman, A ^b   Gomez Abuin, G ^d   Beniwal, P ^b   Blair, E A ^b   Stenson, K M ^b   Portugal, L ^b   Seiwert, T ^a   Williams, R D ^a   Dekker, A J ^a   Witt, M E ^b   Vokes, E E ^a,b   Cohen, E E W ^a  

^a Section Hematology/Oncology   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HOSPITAL ALEMÁN   (Argentina)

Author keywords

Chemoreirradiation; Concurrent chemoradiation; Induction chemotherapy; Recurrent head and neck cancer

Indexed keywords

CARBOPLATIN; CYANOCOBALAMIN; FOLIC ACID; GEMCITABINE; PEMETREXED;

ADULT; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DEHYDRATION; DERMATITIS; DIARRHEA; DRUG TOLERABILITY; DYSPNEA; FACE EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEAD AND NECK CARCINOMA; HEMATEMESIS; HEMATOMA; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; INFECTION; INTENSITY MODULATED RADIATION THERAPY; KIDNEY FAILURE; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DERMATITIS; RADIATION DOSE; SEPSIS; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; THROMBOCYTOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

EID: 80155124269     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq785     Document Type: Article

References (21)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59(4): 225-249.
2. Mell LK, Dignam JJ, Salama JK et al. Predictors of competing mortality in advanced head and neck cancer. J Clin Oncol 2010; 28(1): 15-20.
3. Brockstein B, Haraf DJ, Rademaker AW et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol 2004; 15(8): 1179-1186.
4. Salama JK, Vokes EE. Concurrent chemotherapy and re-irradiation for locoregionally recurrent head and neck cancer. Semin Oncol 2008; 35(3): 251-261.
5. Argiris A, Li Y, Forastiere A. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer 2004; 101(10): 2222-2229.
6. Ahmed SM, Cohen EE. Treatment of squamous cell carcinoma of the head and neck in the metastatic and refractory settings: advances in chemotherapy and the emergence of small molecule epidermal growth factor receptor kinase inhibitors. Curr Cancer Drug Targets 2007; 7(7): 666-673.
7. Stevens KR Jr, Britsch A, Moss WT. High-dose reirradiation of head and neck cancer with curative intent. Int J Radiat Oncol Biol Phys 1994; 29(4): 687-698.
8. Spencer SA, Harris J, Wheeler RH et al. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck 2008; 30(3): 281-288.
9. Salama JK, Vokes EE, Chmura SJ et al. Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2006; 64(2): 382-391.
10. Janot F, de Raucourt D, Benhamou E et al. Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol 2008; 26(34): 5518-5523.
11. Worden FP, Kumar B, Lee JS et al. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol 2008; 26(19): 3138-3146.
12. Pivot X, Raymond E, Laguerre B et al. Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer 2001; 85(5): 649-655.
13. Catimel G, Vermorken JB, Clavel M et al. A phase II study of gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 1994; 5(6): 543-547.
14. Raguse JD, Gath HJ, Bier J et al. Gemcitabine in the treatment of advanced head and neck cancer. Clin Oncol (R Coll Radiol) 2005; 17(6): 425-429.
15. Cohen EE, Lingen MW, Vokes EE. The expanding role of systemic therapy in head and neck cancer. J Clin Oncol 2004; 22(9): 1743-1752.
16. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995; 13(1): 8-10.
17. Macdermed DM, Weichselbaum RR, Salama JK. A rationale for the targeted treatment of oligometastases with radiotherapy. J Surg Oncol 2008; 98(3): 202-206.
18. Choudhury JB. Non-parametric confidence interval estimation for competing risks analysis: application to contraceptive data. Stat Med 2002; 21(8): 1129-1144.
19. Posner MR, Hershock DM, Blajman CR et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357(17): 1705-1715.
20. Vermorken JB, Remenar E, van Herpen C et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357(17): 1695-1704.
21. Salama JK, Stenson KM, Kistner EO et al. Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels. Ann Oncol 2008; 19(10): 1787-1794.